Financials data is unavailable for this security.
Inc stmt in DKKIncome statement in DKK
Year on year
Novo Nordisk A/S grew net income 13.33% from 42.14bn to 47.76bn primarily through revenue growth (126.95bn to 140.80bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 10.91% growth in revenues contributed enough to still see net income improve.
|Net profit margin||33.11%|
|Return on assets||29.15%|
|Return on equity||78.92%|
|Return on investment||57.87%|
Cash flow in DKK
In 2021, cash reserves at
Novo Nordisk A/S fell by 1.51bn. However, the company earned 55.00bn from its operations for a Cash Flow Margin of 39.06%. In addition the company used 31.61bn on investing activities and also paid 25.49bn in financing cash flows.
|Cash flow per share||23.86|
|Price/Cash flow per share||23.43|
|Book value per share||29.24|
|Tangible book value per share||10.20|
Balance sheet in DKK
|Total debt/total equity||0.3829|
|Total debt/total capital||0.2769|
Growth rates in DKK
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 14.29% and 15.15%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
|Div yield(5 year avg)||2.16%|
|Div growth rate (5 year)||6.47%|
|Payout ratio (TTM)||36.62%|
|EPS growth(5 years)||6.74|
|EPS (TTM) vs |
TTM 1 year ago